BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 11283931)

  • 1. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
    Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience.
    Muramaki M; Hara I; Miyake H; Yamada Y; Kawabata G; Kamidono S
    Int J Urol; 2004 Sep; 11(9):768-73. PubMed ID: 15379942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
    Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
    Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
    Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
    Gutierrez-Delgado F; Titov DA; Tjulandin SA; Garin AM
    Neoplasma; 1999; 46(3):190-5. PubMed ID: 10613596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediastinal metastases from testicular nonseminomatous germ cell tumors: patterns of dissemination and predictors of long-term survival with surgery.
    Kesler KA; Brooks JA; Rieger KM; Fineberg NS; Einhorn LH; Brown JW
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):913-23. PubMed ID: 12698156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of chemotherapy for advanced testicular and extragonadal germ cell tumors: a single-center 27-year experience.
    Tanaka T; Kitamura H; Takahashi A; Masumori N; Tsukamoto T
    Jpn J Clin Oncol; 2010 Jan; 40(1):73-8. PubMed ID: 19773268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome.
    Bokemeyer C; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Einhorn L; Nichols CR; Hartmann JT
    Cancer; 2001 Apr; 91(7):1394-401. PubMed ID: 11283942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.
    Shintaku I; Satoh M; Okajima E; Fujimoto H; Kamoto T; Ogawa O; Kawai K; Akaza H; Tsukamoto T; Naito S; Miki T; Arai Y
    Jpn J Clin Oncol; 2008 Apr; 38(4):281-7. PubMed ID: 18321891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
    Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term results of multimodality therapy of testicular germ cell tumor].
    Wang JW; Yang L; Wang JY; Qu T; Cai RG; Huang J; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):382-5. PubMed ID: 12921572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
    J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germ cell tumours of the testis: clinical features, treatment outcome and prognostic factors.
    Bhutani M; Kumar L; Seth A; Thulkar S; Vijayaraghavan M; Kochupillai V
    Natl Med J India; 2002; 15(1):18-21. PubMed ID: 11855586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
    Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
    Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
    Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.